newswire, breaking biotechnology and pharma news

Wednesday, November 21, 2012

Medical Technology Stock Decision Diagnostics (OTCBB: DECN) Lead Product Shasta Genstrip Positions for at-home testing of Blood Glucose Market

New York, New York, Point Roberts, WA - November 21, 2012 ( Newswire), an investor research portal specializing in sector research for independent investors issues an investor alert for Decision Diagnostics Corp. (OTCBB: DECN) for investors following medical technology stocks . The Company's lead product, Shasta Genstrip, is currently in the FDA approval process for at-home testing of blood glucose, currently estimated at $22.5 Billion Worldwide.

According to "There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth.”
Decision Diagnostics Corp. (OTCBB: DECN) GenStrip® Blood Glucose Test Strips
Frequent and accurate testing of blood glucose is essential to the treatment of diabetes. Unfortunately, high costs of testing supplies puts regular monitoring out of reach for many diabetics. GenStrip® Blood Glucose Test Strips make blood glucose testing fast, easy, convenient, and more affordable for anyone living with diabetes. This new diagnostic product is compatible with a family of existing meters provided by the platform manufacturer, but priced significantly (50%) lower. GenStrip is in the final stages of FDA approval.
Become an Investor Ideas member today, login to stock directories and investor newsletter In March 2012 and then again September 2012 representatives of the company and Shasta Technologies LLC met face-to-face with the FDA to ask questions and respond to FDA comments and to present its case in an effort to complete the FDA review process. Subsequently Shasta Technologies LLC and the company have received and responded to a short series of follow up questions and comments by FDA.
Decision Diagnostics Company website
DECN SEC quarterly file
More info on DECN at
About is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow on Twitter!/Investorideas
Follow on Facebook
Follow News on at
Sign up for the free investor news and stock alerts at
Disclaimer/ Disclosure: The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source -

No comments:

Post a Comment